Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
15,419
archived clinical trials in
Pulmonary

28 Day Repeat Dose in Cystic Fibrosis Patients
A Randomized, Double Blind, Parallel Group, Placebo Controlled 28 Day Study to Investigate the Safety, Tolerability and Pharmacodynamics of SB-656933 in Patients With Cystic Fibrosis.
Status: Enrolling
Updated:  10/16/2017
GSK Investigational Site
mi
from
Albany, NY
28 Day Repeat Dose in Cystic Fibrosis Patients
A Randomized, Double Blind, Parallel Group, Placebo Controlled 28 Day Study to Investigate the Safety, Tolerability and Pharmacodynamics of SB-656933 in Patients With Cystic Fibrosis.
Status: Enrolling
Updated: 10/16/2017
GSK Investigational Site
mi
from
Albany, NY
Click here to add this to my saved trials
28 Day Repeat Dose in Cystic Fibrosis Patients
A Randomized, Double Blind, Parallel Group, Placebo Controlled 28 Day Study to Investigate the Safety, Tolerability and Pharmacodynamics of SB-656933 in Patients With Cystic Fibrosis.
Status: Enrolling
Updated:  10/16/2017
GSK Investigational Site
mi
from
Akron, OH
28 Day Repeat Dose in Cystic Fibrosis Patients
A Randomized, Double Blind, Parallel Group, Placebo Controlled 28 Day Study to Investigate the Safety, Tolerability and Pharmacodynamics of SB-656933 in Patients With Cystic Fibrosis.
Status: Enrolling
Updated: 10/16/2017
GSK Investigational Site
mi
from
Akron, OH
Click here to add this to my saved trials
28 Day Repeat Dose in Cystic Fibrosis Patients
A Randomized, Double Blind, Parallel Group, Placebo Controlled 28 Day Study to Investigate the Safety, Tolerability and Pharmacodynamics of SB-656933 in Patients With Cystic Fibrosis.
Status: Enrolling
Updated:  10/16/2017
GSK Investigational Site
mi
from
Cincinnati, OH
28 Day Repeat Dose in Cystic Fibrosis Patients
A Randomized, Double Blind, Parallel Group, Placebo Controlled 28 Day Study to Investigate the Safety, Tolerability and Pharmacodynamics of SB-656933 in Patients With Cystic Fibrosis.
Status: Enrolling
Updated: 10/16/2017
GSK Investigational Site
mi
from
Cincinnati, OH
Click here to add this to my saved trials
28 Day Repeat Dose in Cystic Fibrosis Patients
A Randomized, Double Blind, Parallel Group, Placebo Controlled 28 Day Study to Investigate the Safety, Tolerability and Pharmacodynamics of SB-656933 in Patients With Cystic Fibrosis.
Status: Enrolling
Updated:  10/16/2017
GSK Investigational Site
mi
from
Cleveland, OH
28 Day Repeat Dose in Cystic Fibrosis Patients
A Randomized, Double Blind, Parallel Group, Placebo Controlled 28 Day Study to Investigate the Safety, Tolerability and Pharmacodynamics of SB-656933 in Patients With Cystic Fibrosis.
Status: Enrolling
Updated: 10/16/2017
GSK Investigational Site
mi
from
Cleveland, OH
Click here to add this to my saved trials
28 Day Repeat Dose in Cystic Fibrosis Patients
A Randomized, Double Blind, Parallel Group, Placebo Controlled 28 Day Study to Investigate the Safety, Tolerability and Pharmacodynamics of SB-656933 in Patients With Cystic Fibrosis.
Status: Enrolling
Updated:  10/16/2017
GSK Investigational Site
mi
from
Philadelphia, PA
28 Day Repeat Dose in Cystic Fibrosis Patients
A Randomized, Double Blind, Parallel Group, Placebo Controlled 28 Day Study to Investigate the Safety, Tolerability and Pharmacodynamics of SB-656933 in Patients With Cystic Fibrosis.
Status: Enrolling
Updated: 10/16/2017
GSK Investigational Site
mi
from
Philadelphia, PA
Click here to add this to my saved trials
28 Day Repeat Dose in Cystic Fibrosis Patients
A Randomized, Double Blind, Parallel Group, Placebo Controlled 28 Day Study to Investigate the Safety, Tolerability and Pharmacodynamics of SB-656933 in Patients With Cystic Fibrosis.
Status: Enrolling
Updated:  10/16/2017
GSK Investigational Site
mi
from
Pittsburgh, PA
28 Day Repeat Dose in Cystic Fibrosis Patients
A Randomized, Double Blind, Parallel Group, Placebo Controlled 28 Day Study to Investigate the Safety, Tolerability and Pharmacodynamics of SB-656933 in Patients With Cystic Fibrosis.
Status: Enrolling
Updated: 10/16/2017
GSK Investigational Site
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
28 Day Repeat Dose in Cystic Fibrosis Patients
A Randomized, Double Blind, Parallel Group, Placebo Controlled 28 Day Study to Investigate the Safety, Tolerability and Pharmacodynamics of SB-656933 in Patients With Cystic Fibrosis.
Status: Enrolling
Updated:  10/16/2017
GSK Investigational Site
mi
from
Houston, TX
28 Day Repeat Dose in Cystic Fibrosis Patients
A Randomized, Double Blind, Parallel Group, Placebo Controlled 28 Day Study to Investigate the Safety, Tolerability and Pharmacodynamics of SB-656933 in Patients With Cystic Fibrosis.
Status: Enrolling
Updated: 10/16/2017
GSK Investigational Site
mi
from
Houston, TX
Click here to add this to my saved trials
28 Day Repeat Dose in Cystic Fibrosis Patients
A Randomized, Double Blind, Parallel Group, Placebo Controlled 28 Day Study to Investigate the Safety, Tolerability and Pharmacodynamics of SB-656933 in Patients With Cystic Fibrosis.
Status: Enrolling
Updated:  10/16/2017
GSK Investigational Site
mi
from
Colchester, VT
28 Day Repeat Dose in Cystic Fibrosis Patients
A Randomized, Double Blind, Parallel Group, Placebo Controlled 28 Day Study to Investigate the Safety, Tolerability and Pharmacodynamics of SB-656933 in Patients With Cystic Fibrosis.
Status: Enrolling
Updated: 10/16/2017
GSK Investigational Site
mi
from
Colchester, VT
Click here to add this to my saved trials
28 Day Repeat Dose in Cystic Fibrosis Patients
A Randomized, Double Blind, Parallel Group, Placebo Controlled 28 Day Study to Investigate the Safety, Tolerability and Pharmacodynamics of SB-656933 in Patients With Cystic Fibrosis.
Status: Enrolling
Updated:  10/16/2017
GSK Investigational Site
mi
from
Madison, WI
28 Day Repeat Dose in Cystic Fibrosis Patients
A Randomized, Double Blind, Parallel Group, Placebo Controlled 28 Day Study to Investigate the Safety, Tolerability and Pharmacodynamics of SB-656933 in Patients With Cystic Fibrosis.
Status: Enrolling
Updated: 10/16/2017
GSK Investigational Site
mi
from
Madison, WI
Click here to add this to my saved trials
28 Day Repeat Dose in Cystic Fibrosis Patients
A Randomized, Double Blind, Parallel Group, Placebo Controlled 28 Day Study to Investigate the Safety, Tolerability and Pharmacodynamics of SB-656933 in Patients With Cystic Fibrosis.
Status: Enrolling
Updated:  10/16/2017
GSK Investigational Site
mi
from
Milwaukee, WI
28 Day Repeat Dose in Cystic Fibrosis Patients
A Randomized, Double Blind, Parallel Group, Placebo Controlled 28 Day Study to Investigate the Safety, Tolerability and Pharmacodynamics of SB-656933 in Patients With Cystic Fibrosis.
Status: Enrolling
Updated: 10/16/2017
GSK Investigational Site
mi
from
Milwaukee, WI
Click here to add this to my saved trials
28 Day Repeat Dose in Cystic Fibrosis Patients
A Randomized, Double Blind, Parallel Group, Placebo Controlled 28 Day Study to Investigate the Safety, Tolerability and Pharmacodynamics of SB-656933 in Patients With Cystic Fibrosis.
Status: Enrolling
Updated:  10/16/2017
GSK Investigational Site
mi
from
Toronto,
28 Day Repeat Dose in Cystic Fibrosis Patients
A Randomized, Double Blind, Parallel Group, Placebo Controlled 28 Day Study to Investigate the Safety, Tolerability and Pharmacodynamics of SB-656933 in Patients With Cystic Fibrosis.
Status: Enrolling
Updated: 10/16/2017
GSK Investigational Site
mi
from
Toronto,
Click here to add this to my saved trials
SB-681323 IV for Subjects at Risk of Acute Lung Injury or ARDS
Assessment of the Anti-Inflammatory Activity, Efficacy and Safety of Intravenous SB-681323 in Subjects at Risk for Development of Acute Lung Injury (ALI) or Acute Respiratory Distress Syndrome (ARDS).
Status: Enrolling
Updated:  10/17/2017
GSK Investigational Site
mi
from
Durham, NC
SB-681323 IV for Subjects at Risk of Acute Lung Injury or ARDS
Assessment of the Anti-Inflammatory Activity, Efficacy and Safety of Intravenous SB-681323 in Subjects at Risk for Development of Acute Lung Injury (ALI) or Acute Respiratory Distress Syndrome (ARDS).
Status: Enrolling
Updated: 10/17/2017
GSK Investigational Site
mi
from
Durham, NC
Click here to add this to my saved trials
SB-681323 IV for Subjects at Risk of Acute Lung Injury or ARDS
Assessment of the Anti-Inflammatory Activity, Efficacy and Safety of Intravenous SB-681323 in Subjects at Risk for Development of Acute Lung Injury (ALI) or Acute Respiratory Distress Syndrome (ARDS).
Status: Enrolling
Updated:  10/17/2017
GSK Investigational Site
mi
from
Philadelphia, PA
SB-681323 IV for Subjects at Risk of Acute Lung Injury or ARDS
Assessment of the Anti-Inflammatory Activity, Efficacy and Safety of Intravenous SB-681323 in Subjects at Risk for Development of Acute Lung Injury (ALI) or Acute Respiratory Distress Syndrome (ARDS).
Status: Enrolling
Updated: 10/17/2017
GSK Investigational Site
mi
from
Philadelphia, PA
Click here to add this to my saved trials
SB-681323 IV for Subjects at Risk of Acute Lung Injury or ARDS
Assessment of the Anti-Inflammatory Activity, Efficacy and Safety of Intravenous SB-681323 in Subjects at Risk for Development of Acute Lung Injury (ALI) or Acute Respiratory Distress Syndrome (ARDS).
Status: Enrolling
Updated:  10/17/2017
GSK Investigational Site
mi
from
Lexington, KY
SB-681323 IV for Subjects at Risk of Acute Lung Injury or ARDS
Assessment of the Anti-Inflammatory Activity, Efficacy and Safety of Intravenous SB-681323 in Subjects at Risk for Development of Acute Lung Injury (ALI) or Acute Respiratory Distress Syndrome (ARDS).
Status: Enrolling
Updated: 10/17/2017
GSK Investigational Site
mi
from
Lexington, KY
Click here to add this to my saved trials
SB-681323 IV for Subjects at Risk of Acute Lung Injury or ARDS
Assessment of the Anti-Inflammatory Activity, Efficacy and Safety of Intravenous SB-681323 in Subjects at Risk for Development of Acute Lung Injury (ALI) or Acute Respiratory Distress Syndrome (ARDS).
Status: Enrolling
Updated:  10/17/2017
GSK Investigational Site
mi
from
Winston-Salem, NC
SB-681323 IV for Subjects at Risk of Acute Lung Injury or ARDS
Assessment of the Anti-Inflammatory Activity, Efficacy and Safety of Intravenous SB-681323 in Subjects at Risk for Development of Acute Lung Injury (ALI) or Acute Respiratory Distress Syndrome (ARDS).
Status: Enrolling
Updated: 10/17/2017
GSK Investigational Site
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
SB-681323 IV for Subjects at Risk of Acute Lung Injury or ARDS
Assessment of the Anti-Inflammatory Activity, Efficacy and Safety of Intravenous SB-681323 in Subjects at Risk for Development of Acute Lung Injury (ALI) or Acute Respiratory Distress Syndrome (ARDS).
Status: Enrolling
Updated:  10/17/2017
GSK Investigational Site
mi
from
Pittsburgh, PA
SB-681323 IV for Subjects at Risk of Acute Lung Injury or ARDS
Assessment of the Anti-Inflammatory Activity, Efficacy and Safety of Intravenous SB-681323 in Subjects at Risk for Development of Acute Lung Injury (ALI) or Acute Respiratory Distress Syndrome (ARDS).
Status: Enrolling
Updated: 10/17/2017
GSK Investigational Site
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
SB-681323 IV for Subjects at Risk of Acute Lung Injury or ARDS
Assessment of the Anti-Inflammatory Activity, Efficacy and Safety of Intravenous SB-681323 in Subjects at Risk for Development of Acute Lung Injury (ALI) or Acute Respiratory Distress Syndrome (ARDS).
Status: Enrolling
Updated:  10/17/2017
GSK Investigational Site
mi
from
Nashville, TN
SB-681323 IV for Subjects at Risk of Acute Lung Injury or ARDS
Assessment of the Anti-Inflammatory Activity, Efficacy and Safety of Intravenous SB-681323 in Subjects at Risk for Development of Acute Lung Injury (ALI) or Acute Respiratory Distress Syndrome (ARDS).
Status: Enrolling
Updated: 10/17/2017
GSK Investigational Site
mi
from
Nashville, TN
Click here to add this to my saved trials
Obstructive Sleep Apnea in Pregnancy
Obstructive Sleep Apnea in Pregnancy: Development of a Pregnancy-Specific Screening Tool
Status: Enrolling
Updated:  10/17/2017
Duke Univ Med Ctr
mi
from
Durham, NC
Obstructive Sleep Apnea in Pregnancy
Obstructive Sleep Apnea in Pregnancy: Development of a Pregnancy-Specific Screening Tool
Status: Enrolling
Updated: 10/17/2017
Duke Univ Med Ctr
mi
from
Durham, NC
Click here to add this to my saved trials
Evaluation of Ivacaftor in Patients Using Ataluren for Nonsense Mutations
An Open Label Study to Investigate the Role of Ivacaftor for the Treatment of Cystic Fibrosis in Combination With Ataluren (PTC124) in Cystic Fibrosis Patients Using Ataluren for Nonsense Mutations
Status: Enrolling
Updated:  10/17/2017
University of Alabama at Birmingham
mi
from
Birmingham, AL
Evaluation of Ivacaftor in Patients Using Ataluren for Nonsense Mutations
An Open Label Study to Investigate the Role of Ivacaftor for the Treatment of Cystic Fibrosis in Combination With Ataluren (PTC124) in Cystic Fibrosis Patients Using Ataluren for Nonsense Mutations
Status: Enrolling
Updated: 10/17/2017
University of Alabama at Birmingham
mi
from
Birmingham, AL
Click here to add this to my saved trials
Effects of Continuous Positive Airway Pressure (CPAP) on Glucose Metabolism
Sleep, Obesity, and Metabolism in Normal and Overweight Subjects: Effects of CPAP on Glucose Metabolism
Status: Enrolling
Updated:  10/18/2017
Johns Hopkins Bayview Medical Center
mi
from
Baltimore, MD
Effects of Continuous Positive Airway Pressure (CPAP) on Glucose Metabolism
Sleep, Obesity, and Metabolism in Normal and Overweight Subjects: Effects of CPAP on Glucose Metabolism
Status: Enrolling
Updated: 10/18/2017
Johns Hopkins Bayview Medical Center
mi
from
Baltimore, MD
Click here to add this to my saved trials
Weaning From Mechanical Ventilation Using Permissive Hypercarbia
Weaning From Mechanical Ventilation Using Permissive Hypercarbia
Status: Enrolling
Updated:  10/18/2017
Penn State Milton S. Hershey Medical Center
mi
from
Hershey, PA
Weaning From Mechanical Ventilation Using Permissive Hypercarbia
Weaning From Mechanical Ventilation Using Permissive Hypercarbia
Status: Enrolling
Updated: 10/18/2017
Penn State Milton S. Hershey Medical Center
mi
from
Hershey, PA
Click here to add this to my saved trials
Patient Centered Cloud-based Electronic System: Ambient Warning and Response Evaluation (ProCCESs AWARE)
Patient Centered Cloud-based Electronic System: Ambient Warning and Response Evaluation (ProCCESs AWARE)
Status: Enrolling
Updated:  10/20/2017
Mayo Clinic Arizona
mi
from
Scottsdale, AZ
Patient Centered Cloud-based Electronic System: Ambient Warning and Response Evaluation (ProCCESs AWARE)
Patient Centered Cloud-based Electronic System: Ambient Warning and Response Evaluation (ProCCESs AWARE)
Status: Enrolling
Updated: 10/20/2017
Mayo Clinic Arizona
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Patient Centered Cloud-based Electronic System: Ambient Warning and Response Evaluation (ProCCESs AWARE)
Patient Centered Cloud-based Electronic System: Ambient Warning and Response Evaluation (ProCCESs AWARE)
Status: Enrolling
Updated:  10/20/2017
Mayo Clinic
mi
from
Jacksonville, FL
Patient Centered Cloud-based Electronic System: Ambient Warning and Response Evaluation (ProCCESs AWARE)
Patient Centered Cloud-based Electronic System: Ambient Warning and Response Evaluation (ProCCESs AWARE)
Status: Enrolling
Updated: 10/20/2017
Mayo Clinic
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Patient Centered Cloud-based Electronic System: Ambient Warning and Response Evaluation (ProCCESs AWARE)
Patient Centered Cloud-based Electronic System: Ambient Warning and Response Evaluation (ProCCESs AWARE)
Status: Enrolling
Updated:  10/20/2017
Lawrence Genral Hospital
mi
from
Lawrence, MA
Patient Centered Cloud-based Electronic System: Ambient Warning and Response Evaluation (ProCCESs AWARE)
Patient Centered Cloud-based Electronic System: Ambient Warning and Response Evaluation (ProCCESs AWARE)
Status: Enrolling
Updated: 10/20/2017
Lawrence Genral Hospital
mi
from
Lawrence, MA
Click here to add this to my saved trials
Patient Centered Cloud-based Electronic System: Ambient Warning and Response Evaluation (ProCCESs AWARE)
Patient Centered Cloud-based Electronic System: Ambient Warning and Response Evaluation (ProCCESs AWARE)
Status: Enrolling
Updated:  10/20/2017
Mayo Clinic Rochester
mi
from
Rochester, MN
Patient Centered Cloud-based Electronic System: Ambient Warning and Response Evaluation (ProCCESs AWARE)
Patient Centered Cloud-based Electronic System: Ambient Warning and Response Evaluation (ProCCESs AWARE)
Status: Enrolling
Updated: 10/20/2017
Mayo Clinic Rochester
mi
from
Rochester, MN
Click here to add this to my saved trials
Patient Centered Cloud-based Electronic System: Ambient Warning and Response Evaluation (ProCCESs AWARE)
Patient Centered Cloud-based Electronic System: Ambient Warning and Response Evaluation (ProCCESs AWARE)
Status: Enrolling
Updated:  10/20/2017
OU Medical Center
mi
from
Oklahoma City, OK
Patient Centered Cloud-based Electronic System: Ambient Warning and Response Evaluation (ProCCESs AWARE)
Patient Centered Cloud-based Electronic System: Ambient Warning and Response Evaluation (ProCCESs AWARE)
Status: Enrolling
Updated: 10/20/2017
OU Medical Center
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Patient Centered Cloud-based Electronic System: Ambient Warning and Response Evaluation (ProCCESs AWARE)
Patient Centered Cloud-based Electronic System: Ambient Warning and Response Evaluation (ProCCESs AWARE)
Status: Enrolling
Updated:  10/20/2017
Montefiore Medical Center
mi
from
The Bronx, NY
Patient Centered Cloud-based Electronic System: Ambient Warning and Response Evaluation (ProCCESs AWARE)
Patient Centered Cloud-based Electronic System: Ambient Warning and Response Evaluation (ProCCESs AWARE)
Status: Enrolling
Updated: 10/20/2017
Montefiore Medical Center
mi
from
The Bronx, NY
Click here to add this to my saved trials
A Phase 2a Study to Evaluate Orally Administered ALS-008176 in Adults Hospitalized With a Respiratory Syncytial Virus
A Phase 2a, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Orally Administered ALS-008176 in Adults Hospitalized With a Respiratory Syncytial Virus-Related Illness
Status: Enrolling
Updated:  10/23/2017
Infectious Disease Specialists of Atlanta
mi
from
Atlanta, GA
A Phase 2a Study to Evaluate Orally Administered ALS-008176 in Adults Hospitalized With a Respiratory Syncytial Virus
A Phase 2a, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Orally Administered ALS-008176 in Adults Hospitalized With a Respiratory Syncytial Virus-Related Illness
Status: Enrolling
Updated: 10/23/2017
Infectious Disease Specialists of Atlanta
mi
from
Atlanta, GA
Click here to add this to my saved trials
A Phase 2a Study to Evaluate Orally Administered ALS-008176 in Adults Hospitalized With a Respiratory Syncytial Virus
A Phase 2a, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Orally Administered ALS-008176 in Adults Hospitalized With a Respiratory Syncytial Virus-Related Illness
Status: Enrolling
Updated:  10/23/2017
Lake Internal Med. Assoc.
mi
from
Eustis, FL
A Phase 2a Study to Evaluate Orally Administered ALS-008176 in Adults Hospitalized With a Respiratory Syncytial Virus
A Phase 2a, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Orally Administered ALS-008176 in Adults Hospitalized With a Respiratory Syncytial Virus-Related Illness
Status: Enrolling
Updated: 10/23/2017
Lake Internal Med. Assoc.
mi
from
Eustis, FL
Click here to add this to my saved trials
A Phase 2a Study to Evaluate Orally Administered ALS-008176 in Adults Hospitalized With a Respiratory Syncytial Virus
A Phase 2a, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Orally Administered ALS-008176 in Adults Hospitalized With a Respiratory Syncytial Virus-Related Illness
Status: Enrolling
Updated:  10/23/2017
The Research Center
mi
from
Hialeah, FL
A Phase 2a Study to Evaluate Orally Administered ALS-008176 in Adults Hospitalized With a Respiratory Syncytial Virus
A Phase 2a, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Orally Administered ALS-008176 in Adults Hospitalized With a Respiratory Syncytial Virus-Related Illness
Status: Enrolling
Updated: 10/23/2017
The Research Center
mi
from
Hialeah, FL
Click here to add this to my saved trials
A Phase 2a Study to Evaluate Orally Administered ALS-008176 in Adults Hospitalized With a Respiratory Syncytial Virus
A Phase 2a, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Orally Administered ALS-008176 in Adults Hospitalized With a Respiratory Syncytial Virus-Related Illness
Status: Enrolling
Updated:  10/23/2017
JDH Medical Group
mi
from
Miami, FL
A Phase 2a Study to Evaluate Orally Administered ALS-008176 in Adults Hospitalized With a Respiratory Syncytial Virus
A Phase 2a, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Orally Administered ALS-008176 in Adults Hospitalized With a Respiratory Syncytial Virus-Related Illness
Status: Enrolling
Updated: 10/23/2017
JDH Medical Group
mi
from
Miami, FL
Click here to add this to my saved trials
A Phase 2a Study to Evaluate Orally Administered ALS-008176 in Adults Hospitalized With a Respiratory Syncytial Virus
A Phase 2a, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Orally Administered ALS-008176 in Adults Hospitalized With a Respiratory Syncytial Virus-Related Illness
Status: Enrolling
Updated:  10/23/2017
St Lucie Medical Center
mi
from
Port Saint Lucie, FL
A Phase 2a Study to Evaluate Orally Administered ALS-008176 in Adults Hospitalized With a Respiratory Syncytial Virus
A Phase 2a, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Orally Administered ALS-008176 in Adults Hospitalized With a Respiratory Syncytial Virus-Related Illness
Status: Enrolling
Updated: 10/23/2017
St Lucie Medical Center
mi
from
Port Saint Lucie, FL
Click here to add this to my saved trials
A Phase 2a Study to Evaluate Orally Administered ALS-008176 in Adults Hospitalized With a Respiratory Syncytial Virus
A Phase 2a, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Orally Administered ALS-008176 in Adults Hospitalized With a Respiratory Syncytial Virus-Related Illness
Status: Enrolling
Updated:  10/23/2017
Tampa Genereal Hospital
mi
from
Tampa, FL
A Phase 2a Study to Evaluate Orally Administered ALS-008176 in Adults Hospitalized With a Respiratory Syncytial Virus
A Phase 2a, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Orally Administered ALS-008176 in Adults Hospitalized With a Respiratory Syncytial Virus-Related Illness
Status: Enrolling
Updated: 10/23/2017
Tampa Genereal Hospital
mi
from
Tampa, FL
Click here to add this to my saved trials
A Phase 2a Study to Evaluate Orally Administered ALS-008176 in Adults Hospitalized With a Respiratory Syncytial Virus
A Phase 2a, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Orally Administered ALS-008176 in Adults Hospitalized With a Respiratory Syncytial Virus-Related Illness
Status: Enrolling
Updated:  10/23/2017
Kentucky Lung Clinic, PSC
mi
from
Hazard, KY
A Phase 2a Study to Evaluate Orally Administered ALS-008176 in Adults Hospitalized With a Respiratory Syncytial Virus
A Phase 2a, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Orally Administered ALS-008176 in Adults Hospitalized With a Respiratory Syncytial Virus-Related Illness
Status: Enrolling
Updated: 10/23/2017
Kentucky Lung Clinic, PSC
mi
from
Hazard, KY
Click here to add this to my saved trials
A Phase 2a Study to Evaluate Orally Administered ALS-008176 in Adults Hospitalized With a Respiratory Syncytial Virus
A Phase 2a, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Orally Administered ALS-008176 in Adults Hospitalized With a Respiratory Syncytial Virus-Related Illness
Status: Enrolling
Updated:  10/23/2017
Bronson Methodist Hosp. Ped
mi
from
Kalamazoo, MI
A Phase 2a Study to Evaluate Orally Administered ALS-008176 in Adults Hospitalized With a Respiratory Syncytial Virus
A Phase 2a, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Orally Administered ALS-008176 in Adults Hospitalized With a Respiratory Syncytial Virus-Related Illness
Status: Enrolling
Updated: 10/23/2017
Bronson Methodist Hosp. Ped
mi
from
Kalamazoo, MI
Click here to add this to my saved trials
A Phase 2a Study to Evaluate Orally Administered ALS-008176 in Adults Hospitalized With a Respiratory Syncytial Virus
A Phase 2a, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Orally Administered ALS-008176 in Adults Hospitalized With a Respiratory Syncytial Virus-Related Illness
Status: Enrolling
Updated:  10/23/2017
William Beaumont Hospital
mi
from
Troy, MI
A Phase 2a Study to Evaluate Orally Administered ALS-008176 in Adults Hospitalized With a Respiratory Syncytial Virus
A Phase 2a, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Orally Administered ALS-008176 in Adults Hospitalized With a Respiratory Syncytial Virus-Related Illness
Status: Enrolling
Updated: 10/23/2017
William Beaumont Hospital
mi
from
Troy, MI
Click here to add this to my saved trials
A Phase 2a Study to Evaluate Orally Administered ALS-008176 in Adults Hospitalized With a Respiratory Syncytial Virus
A Phase 2a, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Orally Administered ALS-008176 in Adults Hospitalized With a Respiratory Syncytial Virus-Related Illness
Status: Enrolling
Updated:  10/23/2017
University of Missouri- Clinical Research Center
mi
from
Columbia, MO
A Phase 2a Study to Evaluate Orally Administered ALS-008176 in Adults Hospitalized With a Respiratory Syncytial Virus
A Phase 2a, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Orally Administered ALS-008176 in Adults Hospitalized With a Respiratory Syncytial Virus-Related Illness
Status: Enrolling
Updated: 10/23/2017
University of Missouri- Clinical Research Center
mi
from
Columbia, MO
Click here to add this to my saved trials
A Phase 2a Study to Evaluate Orally Administered ALS-008176 in Adults Hospitalized With a Respiratory Syncytial Virus
A Phase 2a, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Orally Administered ALS-008176 in Adults Hospitalized With a Respiratory Syncytial Virus-Related Illness
Status: Enrolling
Updated:  10/23/2017
Washington Univ School of Med
mi
from
Saint Louis, MO
A Phase 2a Study to Evaluate Orally Administered ALS-008176 in Adults Hospitalized With a Respiratory Syncytial Virus
A Phase 2a, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Orally Administered ALS-008176 in Adults Hospitalized With a Respiratory Syncytial Virus-Related Illness
Status: Enrolling
Updated: 10/23/2017
Washington Univ School of Med
mi
from
Saint Louis, MO
Click here to add this to my saved trials
A Phase 2a Study to Evaluate Orally Administered ALS-008176 in Adults Hospitalized With a Respiratory Syncytial Virus
A Phase 2a, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Orally Administered ALS-008176 in Adults Hospitalized With a Respiratory Syncytial Virus-Related Illness
Status: Enrolling
Updated:  10/23/2017
Westmead Hospital
mi
from
Northmead,
A Phase 2a Study to Evaluate Orally Administered ALS-008176 in Adults Hospitalized With a Respiratory Syncytial Virus
A Phase 2a, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Orally Administered ALS-008176 in Adults Hospitalized With a Respiratory Syncytial Virus-Related Illness
Status: Enrolling
Updated: 10/23/2017
Westmead Hospital
mi
from
Northmead,
Click here to add this to my saved trials
A Pilot Study of Combined Cycle Ergometry and Amino Acids in the ICU
A Pilot Study of Combined Cycle Ergometry and Amino Acids in the ICU
Status: Enrolling
Updated:  10/24/2017
University of Vermont College of Medicine
mi
from
Burlington, VT
A Pilot Study of Combined Cycle Ergometry and Amino Acids in the ICU
A Pilot Study of Combined Cycle Ergometry and Amino Acids in the ICU
Status: Enrolling
Updated: 10/24/2017
University of Vermont College of Medicine
mi
from
Burlington, VT
Click here to add this to my saved trials
Nebulized Hypertonic Saline for Inpatient Use in COPD
Nebulized Hypertonic Saline for Inpatient Use in Chronic Obstructive Pulmonary Disease
Status: Enrolling
Updated:  10/26/2017
Doctors Hospital
mi
from
Columbus, OH
Nebulized Hypertonic Saline for Inpatient Use in COPD
Nebulized Hypertonic Saline for Inpatient Use in Chronic Obstructive Pulmonary Disease
Status: Enrolling
Updated: 10/26/2017
Doctors Hospital
mi
from
Columbus, OH
Click here to add this to my saved trials
A Study of Oral Vismodegib in Combination With Pirfenidone in Participants With Idiopathic Pulmonary Fibrosis
A Single Arm, Multicenter, Open-label, Phase 1b Study to Assess the Safety and Tolerability of Oral Vismodegib in Combination With Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis
Status: Enrolling
Updated:  10/26/2017
Scripps Clinic
mi
from
La Jolla, CA
A Study of Oral Vismodegib in Combination With Pirfenidone in Participants With Idiopathic Pulmonary Fibrosis
A Single Arm, Multicenter, Open-label, Phase 1b Study to Assess the Safety and Tolerability of Oral Vismodegib in Combination With Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis
Status: Enrolling
Updated: 10/26/2017
Scripps Clinic
mi
from
La Jolla, CA
Click here to add this to my saved trials
A Study of Oral Vismodegib in Combination With Pirfenidone in Participants With Idiopathic Pulmonary Fibrosis
A Single Arm, Multicenter, Open-label, Phase 1b Study to Assess the Safety and Tolerability of Oral Vismodegib in Combination With Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis
Status: Enrolling
Updated:  10/26/2017
Central Florida Pulmonary Group, PA
mi
from
Orlando, FL
A Study of Oral Vismodegib in Combination With Pirfenidone in Participants With Idiopathic Pulmonary Fibrosis
A Single Arm, Multicenter, Open-label, Phase 1b Study to Assess the Safety and Tolerability of Oral Vismodegib in Combination With Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis
Status: Enrolling
Updated: 10/26/2017
Central Florida Pulmonary Group, PA
mi
from
Orlando, FL
Click here to add this to my saved trials
A Study of Oral Vismodegib in Combination With Pirfenidone in Participants With Idiopathic Pulmonary Fibrosis
A Single Arm, Multicenter, Open-label, Phase 1b Study to Assess the Safety and Tolerability of Oral Vismodegib in Combination With Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis
Status: Enrolling
Updated:  10/26/2017
Suburban Lung Associates
mi
from
Elk Grove, IL
A Study of Oral Vismodegib in Combination With Pirfenidone in Participants With Idiopathic Pulmonary Fibrosis
A Single Arm, Multicenter, Open-label, Phase 1b Study to Assess the Safety and Tolerability of Oral Vismodegib in Combination With Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis
Status: Enrolling
Updated: 10/26/2017
Suburban Lung Associates
mi
from
Elk Grove, IL
Click here to add this to my saved trials
A Study of Oral Vismodegib in Combination With Pirfenidone in Participants With Idiopathic Pulmonary Fibrosis
A Single Arm, Multicenter, Open-label, Phase 1b Study to Assess the Safety and Tolerability of Oral Vismodegib in Combination With Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis
Status: Enrolling
Updated:  10/26/2017
Medical Consultants, PC ; Pulmonary
mi
from
Muncie, IN
A Study of Oral Vismodegib in Combination With Pirfenidone in Participants With Idiopathic Pulmonary Fibrosis
A Single Arm, Multicenter, Open-label, Phase 1b Study to Assess the Safety and Tolerability of Oral Vismodegib in Combination With Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis
Status: Enrolling
Updated: 10/26/2017
Medical Consultants, PC ; Pulmonary
mi
from
Muncie, IN
Click here to add this to my saved trials
A Study of Oral Vismodegib in Combination With Pirfenidone in Participants With Idiopathic Pulmonary Fibrosis
A Single Arm, Multicenter, Open-label, Phase 1b Study to Assess the Safety and Tolerability of Oral Vismodegib in Combination With Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis
Status: Enrolling
Updated:  10/26/2017
University of Louisville
mi
from
Louisville, KY
A Study of Oral Vismodegib in Combination With Pirfenidone in Participants With Idiopathic Pulmonary Fibrosis
A Single Arm, Multicenter, Open-label, Phase 1b Study to Assess the Safety and Tolerability of Oral Vismodegib in Combination With Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis
Status: Enrolling
Updated: 10/26/2017
University of Louisville
mi
from
Louisville, KY
Click here to add this to my saved trials
A Study of Oral Vismodegib in Combination With Pirfenidone in Participants With Idiopathic Pulmonary Fibrosis
A Single Arm, Multicenter, Open-label, Phase 1b Study to Assess the Safety and Tolerability of Oral Vismodegib in Combination With Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis
Status: Enrolling
Updated:  10/26/2017
Tulane University Medical School
mi
from
New Orleans, LA
A Study of Oral Vismodegib in Combination With Pirfenidone in Participants With Idiopathic Pulmonary Fibrosis
A Single Arm, Multicenter, Open-label, Phase 1b Study to Assess the Safety and Tolerability of Oral Vismodegib in Combination With Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis
Status: Enrolling
Updated: 10/26/2017
Tulane University Medical School
mi
from
New Orleans, LA
Click here to add this to my saved trials
A Study of Oral Vismodegib in Combination With Pirfenidone in Participants With Idiopathic Pulmonary Fibrosis
A Single Arm, Multicenter, Open-label, Phase 1b Study to Assess the Safety and Tolerability of Oral Vismodegib in Combination With Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis
Status: Enrolling
Updated:  10/26/2017
Steward St. Elizabeth's Medical Center ; Pulmonary, Critical Care and Sleep Medicine
mi
from
Boston, MA
A Study of Oral Vismodegib in Combination With Pirfenidone in Participants With Idiopathic Pulmonary Fibrosis
A Single Arm, Multicenter, Open-label, Phase 1b Study to Assess the Safety and Tolerability of Oral Vismodegib in Combination With Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis
Status: Enrolling
Updated: 10/26/2017
Steward St. Elizabeth's Medical Center ; Pulmonary, Critical Care and Sleep Medicine
mi
from
Boston, MA
Click here to add this to my saved trials
A Study of Oral Vismodegib in Combination With Pirfenidone in Participants With Idiopathic Pulmonary Fibrosis
A Single Arm, Multicenter, Open-label, Phase 1b Study to Assess the Safety and Tolerability of Oral Vismodegib in Combination With Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis
Status: Enrolling
Updated:  10/26/2017
Creighton University Medical Center
mi
from
Omaha, NE
A Study of Oral Vismodegib in Combination With Pirfenidone in Participants With Idiopathic Pulmonary Fibrosis
A Single Arm, Multicenter, Open-label, Phase 1b Study to Assess the Safety and Tolerability of Oral Vismodegib in Combination With Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis
Status: Enrolling
Updated: 10/26/2017
Creighton University Medical Center
mi
from
Omaha, NE
Click here to add this to my saved trials
A Study of Oral Vismodegib in Combination With Pirfenidone in Participants With Idiopathic Pulmonary Fibrosis
A Single Arm, Multicenter, Open-label, Phase 1b Study to Assess the Safety and Tolerability of Oral Vismodegib in Combination With Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis
Status: Enrolling
Updated:  10/26/2017
Allied Clinical Research
mi
from
Reno, NV
A Study of Oral Vismodegib in Combination With Pirfenidone in Participants With Idiopathic Pulmonary Fibrosis
A Single Arm, Multicenter, Open-label, Phase 1b Study to Assess the Safety and Tolerability of Oral Vismodegib in Combination With Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis
Status: Enrolling
Updated: 10/26/2017
Allied Clinical Research
mi
from
Reno, NV
Click here to add this to my saved trials